IL6 and hepatocellular carcinoma: A previous study71 also reported that IL‐6 level was a novel prognostic biomarker for patients with advanced HCC treated with Atezo/Bev, revealing significantly shorter PFS and OS periods in the IL‐6‐high group than in the IL‐6‐low group, which is consistent with our study in terms of OS by subgroup analyses (mOS, 25.5 vs. 19.6 months; p = 0.0373).